USFDAAug 10, 2026, 07:02 AM
Quantum BioPharma Gets FDA Clearance for Lucid-MS Phase 2 Trial
AI Summary
Quantum BioPharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302). This approval allows the company to immediately advance its patented, first-in-class multiple sclerosis program into Phase 2 clinical development. Lucid-MS is designed to provide neuroprotection through the inhibition of demyelination, addressing a significant unmet medical need in the progressive forms of MS, a market projected to reach $1.31 billion by 2026.
Key Highlights
- FDA approved Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302).
- Clearance enables immediate advancement into Phase 2 clinical development for progressive MS.
- Lucid-MS is a patented, first-in-class neuroprotective therapy targeting demyelination.
- Progressive MS market projected to expand from $1.16 billion in 2025 to $1.31 billion by 2026.
- Overall global MS therapeutics market anticipated to reach $38.62 billion by 2030.
- Phase 2 trial will be randomized, double-blind, placebo-controlled.
- Company is partnering with a global clinical research organization; site selection underway.
Price Impact
More from QNTM